Advicenne
Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases in France and internationally. It offers Sibnayal for the treatment of metabolic disorders, distal renal tubular acidosis, and cystinuria. The company also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or co… Read more
Advicenne (ALDVI) - Total Liabilities
Latest total liabilities as of June 2025: €30.73 Million EUR
Based on the latest financial reports, Advicenne (ALDVI) has total liabilities worth €30.73 Million EUR as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Advicenne - Total Liabilities Trend (2014–2024)
This chart illustrates how Advicenne's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Advicenne Competitors by Total Liabilities
The table below lists competitors of Advicenne ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Albert David Limited
NSE:ALBERTDAVD
|
India | ₹1.39 Billion |
|
Lifestyle Global Enterprise
TWO:8066
|
Taiwan | NT$901.60 Million |
|
Mahindra EPC Irrigation Limited
NSE:MAHEPC
|
India | ₹1.27 Billion |
|
Bflysoft Co. Ltd.
KQ:148780
|
Korea | ₩4.80 Billion |
|
Spirit Technology Solutions Ltd
AU:ST1
|
Australia | AU$74.11 Million |
|
Sonic Interfreight Public Company Limited
BK:SONIC
|
Thailand | ฿438.37 Million |
Liability Composition Analysis (2014–2024)
This chart breaks down Advicenne's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.59 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.05 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 4.57 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Advicenne's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Advicenne (2014–2024)
The table below shows the annual total liabilities of Advicenne from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €28.58 Million | +17.24% |
| 2023-12-31 | €24.38 Million | -2.00% |
| 2022-12-31 | €24.88 Million | +33.94% |
| 2021-12-31 | €18.57 Million | -10.42% |
| 2020-12-31 | €20.73 Million | +245.80% |
| 2019-12-31 | €6.00 Million | +69.15% |
| 2018-12-31 | €3.54 Million | -30.59% |
| 2017-12-31 | €5.11 Million | -39.26% |
| 2016-12-31 | €8.41 Million | +80.80% |
| 2015-12-31 | €4.65 Million | +230.26% |
| 2014-12-31 | €1.41 Million | -- |